Ohtuvayre (Ensifentrine) - Is Ensifentrine a new drug for the treatment of COPD?

Ohtuvayre (Ensifentrine) - Ensefentine is a novel phosphodiesterase 3 and 4 inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The drug is administered via a nebulizer and its mechanism of action is primarily characterized by bronchodilation and anti-inflammatory effects, which have been confirmed in in vitro and in vivo studies.

In two clinical trialsENHANCE-1 and ENHANCE-2, approximately 1,500 patients with moderate to severe COPD were randomly assigned to the exefantine group and the placebo group, and the treatment duration was mostly 24 weeks. The results of the study showed that the forced expiratory volume in 1 second (FEV1) of patients in the exefentine group was significantly improved, with an average increase of approximately 91 ml. In addition, the proportion of patients with moderate to severe exacerbations was lower in the exefentine group, about 8% versus 15%. Although one study found improvements in self-reported daily symptoms in the exefentine group, overall no major adverse effects were observed.

Exefentine is officially approved for the maintenance treatment of COPD in adults. It is administered in a 3 mg vial with a standard jet nebulizer for use twice daily. However, it is important to note that this drug is not indicated for the treatment of acute exacerbations of COPD or acute bronchospasm.

Special attention needs to be paid to the patient's mental health when using exefentine. There have been reports that some patients may experience"psychiatric adverse reactions, including depressive thoughts." Therefore, clinicians should carefully weigh the risks and benefits when prescribing them to patients with a history of depression or related disorders to ensure patient safety and therapeutic efficacy. ”

References:https://www.jwatch.org/na57803/2024/08/13/ensifentrine-newly-approved-maintenance-treatment-patients